Arian Hatefi
Research Subjects
Arian Hatefi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Luke Nelson Allen
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
3 shared publications - Anton L. V. Avanceña
Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, USA
1 shared publication - Bawa Singh
Department of South and Central Asian Studies, School of International Studies, Central University of Punjab, Bathinda, India
1 shared publication - Daria Berlina
World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland
1 shared publication - K. Srikanth Reddy
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
1 shared publication - Lina Mahy
Multisectoral Action in Food Systems, World Health Organization
1 shared publication
Latest Publications
- Open Access
- 14 March 2024
- Published by Maad Rayan Publishing Company in Health Promotion Perspectives
- Vol. 14 (1) , 9-18
Pandemic treaty as an instrument to strengthen global health security: Global health diplomacy at its crux
Background: The World Health Assembly (WHA), on 1st December 2021, unanimously agreed to launch a global process to draft and negotiate a convention, agreement, or other international instrument under the World Health Organization’s (WHO’s) constitution to strengthen pandemic prevention, preparedness, and response. We aimed to explore the role of global health diplomacy (GHD) in pandemic treaty negotiations by providing deep insight into the ongoing drafting process under the WHO leadership. Methods: We conducted a narrative review by searching Scopus, Web of Sciences, PubMed, MEDLINE, and Google Scholar search engine using the keywords "Pandemic Treaty," OR "International Health Regulations," OR "International conventions," OR "International treaties" in the context of recent COVID-19 pandemic. Besides, we included articles recommending the need for GHD, leadership and governance mechanisms for this international treaty drafting approved by the WHA. Results: Amid the COVID-19 pandemic, the concept of GHD bolstered the international system and remained high on the agendas of many national, regional and global platforms. As per Article 19 of the WHO constitution, the Assembly established an intergovernmental negotiating body (INB) to draft and negotiate this convention/ agreement to protect the world from disease outbreaks of pandemic potential. Since GHD has helped to strengthen international cooperation in health systems and address inequities in achieving health-related global targets, there is a great scope for the successful drafting of this pandemic treaty. Conclusion: The pandemic treaty is a defining moment in global health governance, particularly the pandemic governance reforms. However, the treaty’s purpose will only be served if the equity considerations are optimized, accountability mechanisms are established, and a sense of shared responsibility is embraced. While fulfilling treaty commitments might be complex and challenging, it provides an opportunity to rethink and build resilient systems for pandemic preparedness and response in the future.
- 14 March 2024
- Published by Maad Rayan Publishing Company in Health Promotion Perspectives
- Vol. 14 (1) , 9-18
Open AccessPandemic treaty as an instrument to strengthen global health security: Global health diplomacy at its crux
Background: The World Health Assembly (WHA), on 1st December 2021, unanimously agreed to launch a global process to draft and negotiate a convention, agreement, or other international instrument under the World Health Organization’s (WHO’s) constitution to strengthen pandemic prevention, preparedness, and response. We aimed to explore the role of global health diplomacy (GHD) in pandemic treaty negotiations by providing deep insight into the ongoing drafting process under the WHO leadership. Methods: We conducted a narrative review by searching Scopus, Web of Sciences, PubMed, MEDLINE, and Google Scholar search engine using the keywords "Pandemic Treaty," OR "International Health Regulations," OR "International conventions," OR "International treaties" in the context of recent COVID-19 pandemic. Besides, we included articles recommending the need for GHD, leadership and governance mechanisms for this international treaty drafting approved by the WHA. Results: Amid the COVID-19 pandemic, the concept of GHD bolstered the international system and remained high on the agendas of many national, regional and global platforms. As per Article 19 of the WHO constitution, the Assembly established an intergovernmental negotiating body (INB) to draft and negotiate this convention/ agreement to protect the world from disease outbreaks of pandemic potential. Since GHD has helped to strengthen international cooperation in health systems and address inequities in achieving health-related global targets, there is a great scope for the successful drafting of this pandemic treaty. Conclusion: The pandemic treaty is a defining moment in global health governance, particularly the pandemic governance reforms. However, the treaty’s purpose will only be served if the equity considerations are optimized, accountability mechanisms are established, and a sense of shared responsibility is embraced. While fulfilling treaty commitments might be complex and challenging, it provides an opportunity to rethink and build resilient systems for pandemic preparedness and response in the future.
- Open Access
- 3 July 2023
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 89 (1) , 46
Engaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create “Shared Value?”
Noncommunicable diseases (NCDs) are the leading cause of premature mortality worldwide. Corporate interests are sometimes well-aligned with public health, but profiteering from the consumption of products that are known to be the major contributors to the noncommunicable disease burden undermines public health. This paper describes the key industry actors shaping the NCD landscape; highlights the unhealthy commodities’ impact on health and the growing burden of NCDs; and outlines challenges and opportunities to reduce exposure to those risk factors. Corporations deploy a wide array of strategies to maximize profits at the expense of health, including sophisticated marketing techniques, interference in the policy-making process, opposition and distortion of research and evidence, and whitewashing of health-harming activities through corporate social responsibility initiatives. There can be no shared value for industries that sell goods that harm health irrespective of consumption patterns (such as tobacco and likely alcohol), so government actions such as regulation and legislation are the only viable policy instruments. Where shared value is possible (for example, with the food industry), industry engagement can potentially realign corporate interests with the public health interest for mutual benefit. Deliberate, careful, and nuanced approaches to engagement are required.
- 3 July 2023
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 89 (1) , 46
Open AccessEngaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create “Shared Value?”
Noncommunicable diseases (NCDs) are the leading cause of premature mortality worldwide. Corporate interests are sometimes well-aligned with public health, but profiteering from the consumption of products that are known to be the major contributors to the noncommunicable disease burden undermines public health. This paper describes the key industry actors shaping the NCD landscape; highlights the unhealthy commodities’ impact on health and the growing burden of NCDs; and outlines challenges and opportunities to reduce exposure to those risk factors. Corporations deploy a wide array of strategies to maximize profits at the expense of health, including sophisticated marketing techniques, interference in the policy-making process, opposition and distortion of research and evidence, and whitewashing of health-harming activities through corporate social responsibility initiatives. There can be no shared value for industries that sell goods that harm health irrespective of consumption patterns (such as tobacco and likely alcohol), so government actions such as regulation and legislation are the only viable policy instruments. Where shared value is possible (for example, with the food industry), industry engagement can potentially realign corporate interests with the public health interest for mutual benefit. Deliberate, careful, and nuanced approaches to engagement are required.
- Open Access
- 13 December 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (1) , e30-E30
Universal health coverage is the vital link when health care is a public health good
- 13 December 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 11 (1) , e30-E30
Open AccessUniversal health coverage is the vital link when health care is a public health good
- 1 October 2020
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 35 (8) , 1133-1136
Global-scale action in health: a common language is a critical starting point to bolster global health financing
Koplan et al. (2009) wrote of global health:
- 1 October 2020
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 35 (8) , 1133-1136
Global-scale action in health: a common language is a critical starting point to bolster global health financing
Koplan et al. (2009) wrote of global health:
- Open Access
- 12 June 2018
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 96 (8) , 586-588
Global susceptibility and response to noncommunicable diseases
- 12 June 2018
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 96 (8) , 586-588
Open AccessGlobal susceptibility and response to noncommunicable diseases
- Open Access
- 21 May 2018
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 72 (8) , 665-667
Donors, non-communicable diseases and universal health coverage to high-quality healthcare: an opportunity for action on global functions for health
In years past, the face of the global burden of disease was a rural child suffering undernutrition and infections in a low-income country. The case for donor intervention—both bilateral and philanthropic—was morally, technically and economically clear. Today, however, it is more commonly an urban adult suffering multiple chronic diseases in a middle-income country. How could donors provide universal health coverage (UHC) or meet such an expansive need for healthcare services? Would they invest in adults who have already had a shot at life and whose lifestyle choices are supposedly to blame? What role could they have in a country with resources? These questions need answers. In 2013, the Lancet Commission on Investing in Health (CIH) grouped the global health agenda into three categories: the unfinished agenda to reduce disparities in key infectious diseases and reproductive, maternal and child health; the emerging agenda to curb non-communicable diseases (NCDs) and injuries; and the cost agenda to provide universal coverage to high-quality healthcare (figure 1).1 Since that time, pandemic preparedness has yet again emerged as an additional priority. The donor response to these challenges primarily exists on two levels: global functions, which transcend national sovereignty to provide globally dispersible benefits, and country-specific functions, which are targeted interventions that improve the health of any individual country (figure 1).2 3 Overwhelmingly, donors have focused their efforts on country-specific functions for the unfinished agenda, or as of late, on global functions for infectious diseases. Left unreconciled is the pressing need to address the global NCD crisis with strong health systems that equitably cover everyone. Figure 1 Global functions will remain important in global health, while country-specific functions will decrease as countries transition. Both will continue to support the major global health priorities. Adapted from Jamison et al .3 That burden is enormous. NCDs …
- 21 May 2018
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 72 (8) , 665-667
Open AccessDonors, non-communicable diseases and universal health coverage to high-quality healthcare: an opportunity for action on global functions for health
In years past, the face of the global burden of disease was a rural child suffering undernutrition and infections in a low-income country. The case for donor intervention—both bilateral and philanthropic—was morally, technically and economically clear. Today, however, it is more commonly an urban adult suffering multiple chronic diseases in a middle-income country. How could donors provide universal health coverage (UHC) or meet such an expansive need for healthcare services? Would they invest in adults who have already had a shot at life and whose lifestyle choices are supposedly to blame? What role could they have in a country with resources? These questions need answers. In 2013, the Lancet Commission on Investing in Health (CIH) grouped the global health agenda into three categories: the unfinished agenda to reduce disparities in key infectious diseases and reproductive, maternal and child health; the emerging agenda to curb non-communicable diseases (NCDs) and injuries; and the cost agenda to provide universal coverage to high-quality healthcare (figure 1).1 Since that time, pandemic preparedness has yet again emerged as an additional priority. The donor response to these challenges primarily exists on two levels: global functions, which transcend national sovereignty to provide globally dispersible benefits, and country-specific functions, which are targeted interventions that improve the health of any individual country (figure 1).2 3 Overwhelmingly, donors have focused their efforts on country-specific functions for the unfinished agenda, or as of late, on global functions for infectious diseases. Left unreconciled is the pressing need to address the global NCD crisis with strong health systems that equitably cover everyone. Figure 1 Global functions will remain important in global health, while country-specific functions will decrease as countries transition. Both will continue to support the major global health priorities. Adapted from Jamison et al .3 That burden is enormous. NCDs …
- Open Access
- 1 December 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (12) , e1183
The costs of reaching the health-related SDGs
- 1 December 2017
- Published by Elsevier in The Lancet Global Health
- Vol. 5 (12) , e1183
Open AccessThe costs of reaching the health-related SDGs
- Open Access
- 12 December 2016
- Published by Springer Nature in Malaria Journal
- Vol. 15 (1) , 1-14
The economics of malaria control and elimination: a systematic review
Declining donor funding and competing health priorities threaten the sustainability of malaria programmes. Elucidating the cost and benefits of continued investments in malaria could encourage sustained political and financial commitments. The evidence, although available, remains disparate. This paper reviews the existing literature on the economic and financial cost and return of malaria control, elimination and eradication. A review of articles that were published on or before September 2014 on the cost and benefits of malaria control and elimination was performed. Studies were classified based on their scope and were analysed according to two major categories: cost of malaria control and elimination to a health system, and cost-benefit studies. Only studies involving more than two control or elimination interventions were included. Outcomes of interest were total programmatic cost, cost per capita, and benefit-cost ratios (BCRs). All costs were converted to 2013 US$ for standardization. Of the 6425 articles identified, 54 studies were included in this review. Twenty-two were focused on elimination or eradication while 32 focused on intensive control. Forty-eight per cent of studies included in this review were published on or after 2000. Overall, the annual per capita cost of malaria control to a health system ranged from $0.11 to $39.06 (median: $2.21) while that for malaria elimination ranged from $0.18 to $27 (median: $3.00). BCRs of investing in malaria control and elimination ranged from 2.4 to over 145. Overall, investments needed for malaria control and elimination varied greatly amongst the various countries and contexts. While the cost of elimination in most cases was greater than the cost of control, the benefits greatly outweighed the cost. Information from this review provides guidance to national malaria programmes on the cost and benefits of malaria elimination in the absence of data. Importantly, the review highlights the need for more robust economic analyses using standard inputs and methods to strengthen the evidence needed for sustained financing for malaria elimination.
- 12 December 2016
- Published by Springer Nature in Malaria Journal
- Vol. 15 (1) , 1-14
Open AccessThe economics of malaria control and elimination: a systematic review
Declining donor funding and competing health priorities threaten the sustainability of malaria programmes. Elucidating the cost and benefits of continued investments in malaria could encourage sustained political and financial commitments. The evidence, although available, remains disparate. This paper reviews the existing literature on the economic and financial cost and return of malaria control, elimination and eradication. A review of articles that were published on or before September 2014 on the cost and benefits of malaria control and elimination was performed. Studies were classified based on their scope and were analysed according to two major categories: cost of malaria control and elimination to a health system, and cost-benefit studies. Only studies involving more than two control or elimination interventions were included. Outcomes of interest were total programmatic cost, cost per capita, and benefit-cost ratios (BCRs). All costs were converted to 2013 US$ for standardization. Of the 6425 articles identified, 54 studies were included in this review. Twenty-two were focused on elimination or eradication while 32 focused on intensive control. Forty-eight per cent of studies included in this review were published on or after 2000. Overall, the annual per capita cost of malaria control to a health system ranged from $0.11 to $39.06 (median: $2.21) while that for malaria elimination ranged from $0.18 to $27 (median: $3.00). BCRs of investing in malaria control and elimination ranged from 2.4 to over 145. Overall, investments needed for malaria control and elimination varied greatly amongst the various countries and contexts. While the cost of elimination in most cases was greater than the cost of control, the benefits greatly outweighed the cost. Information from this review provides guidance to national malaria programmes on the cost and benefits of malaria elimination in the absence of data. Importantly, the review highlights the need for more robust economic analyses using standard inputs and methods to strengthen the evidence needed for sustained financing for malaria elimination.